Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This filing is a Form 6-K reporting the Quarterly Securities Report for the nine-month period and three-month quarter ended December 31, 2018. The report was filed with the Kanto Local Finance Bureau in Japan on February 14, 2019. Takeda is a global pharmaceutical group focused on gastroenterology, oncology, and neuroscience. A significant subsequent event noted is the completion of the acquisition of Shire plc on January 8, 2019.
Key Financial Metrics (Nine Months Ended Dec 31, 2018)
| Metric | 2018 (JPY Billion) | 2017 (JPY Billion) | Change |
|---|---|---|---|
| Revenue | 1,380.0 | 1,369.6 | +0.8% |
| Operating Profit | 284.4 | 322.3 | -11.7% |
| Profit Before Tax | 208.4 | 287.9 | -27.6% |
| Net Profit (Attributable to Owners) | 164.4 | 240.9 | -31.7% |
| Basic EPS | 209.87 JPY | 308.59 JPY | -32.0% |
| Operating Cash Flow | 211.0 | 252.1 | -16.3% |
| Total Assets | 5,767.2 | 4,410.6 | +30.8% |
| Total Equity | 2,042.6 | 2,134.1 | -4.3% |
| Cash & Equivalents | 297.9 | 440.3 | -32.3% |
Debt & Liquidity: Total bonds and loans increased significantly to 2,548.8 billion JPY (carrying amount 1,728.4 billion JPY for bonds) primarily due to issuances to finance the Shire acquisition. Cash and cash equivalents decreased to 297.9 billion JPY, largely due to payments into restricted deposits for the Shire deal.
Material Changes vs. Prior Period
- Revenue: Reported revenue growth was flat (+0.8%) due to divestitures (-37.9 billion JPY) and unfavorable foreign exchange rates. However, Underlying Revenue (excluding FX and divestitures) grew by +4.8%, driven by a +10.5% increase in Growth Drivers (Gastroenterology, Oncology, Neuroscience).
- Profitability: Net profit declined significantly (-31.7%) primarily due to a decrease in operating profit, increased net financial expenses (including Shire acquisition costs), and higher losses from associates (Teva Takeda Pharma Ltd.).
- Operating Profit: Decreased by 11.7% to 284.4 billion JPY. This was impacted by the absence of a 106.3 billion JPY gain on the sale of Wako Pure Chemical Industries recorded in the prior year. SG&A expenses decreased slightly, offset by 11.0 billion JPY in Shire acquisition-related costs.
- Balance Sheet: Total assets rose by 1,660.8 billion JPY, driven by a 1,477.6 billion JPY increase in other financial assets (restricted deposits for Shire). Total liabilities increased by 1,635.6 billion JPY due to new bond issuances.
Guidance, Outlook, and Risks
- Shire Acquisition: Takeda completed the acquisition of Shire plc on January 8, 2019, for a total consideration of approximately 6.16 trillion JPY. This expands Takeda's portfolio into Rare Diseases and Plasma Derived Therapies. The filing notes that initial accounting for this business combination was not complete at the time of issuance.
- Underlying Performance: Management highlights strong underlying growth metrics: Underlying Core Earnings grew +32.3% and Underlying Core EPS grew +34.2%, reflecting the Global Opex Initiative and favorable sales mix.
- R&D Pipeline: Key progress includes FDA/EMA approvals for ALUNBRIG (lung cancer) and TRINTELLIX (depression), and positive Phase 3 data for NINLARO (multiple myeloma) and ADCETRIS (Hodgkin lymphoma).
- Risks: No significant changes to risk factors were disclosed compared to the annual report, other than the execution risks associated with the Shire integration. Litigation regarding ACTOS (bladder cancer claims) remains pending in Louisiana, though Mississippi settled in November 2018.
Key Facts for Investor Verification
- Shire Integration: Verify the final purchase price allocation and the impact of the Shire acquisition on the full-year 2019 results, as the Q3 report does not include Shire's financials.
- Underlying vs. GAAP: Note the divergence between reported GAAP profit (down 31.7%) and underlying core earnings (up 32.3%) driven by one-time gains in the prior year and acquisition costs in the current year.
- Debt Levels: Confirm the total debt load post-Shire acquisition, as bonds and loans increased by over 1.5 trillion JPY in Q3 alone to fund the deal.
- Associate Losses: Review the impact of the impairment charge recognized by Teva Takeda Pharma Ltd. (an associate), which contributed 44.0 billion JPY to the loss from equity method investments.
- Divestitures: Assess the long-term impact of the divestiture of 7 long-listed products in Japan to Teva Takeda Yakuhin Ltd., which negatively impacted revenue by 18.6 billion JPY in this period.